Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.66 |
| ▸ | PPARG | P37231 | 1/20 | 0.66 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517462 | 0.87 | MEN1 (0.70) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL24038923 | 0.87 | MEN1 (0.70) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL25525653 | 0.85 | MEN1 (0.64) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL25527641 | 0.84 | MEN1 (0.62) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL25419311 | 0.84 | MEN1 (0.65) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL24039061 | 0.84 | MEN1 (0.81) | POLBMEN1KMT2ATDP1PPARG | |
| SCHEMBL29436188 | 0.83 | KDM4E (0.60) | POLBMEN1KMT2AUSP2LMNA | |
| SCHEMBL23495113 | 0.83 | KDM4E (0.60) | POLBMEN1KMT2AUSP2LMNA | |
| SCHEMBL29436202 | 0.81 | MEN1 (0.61) | POLBMEN1KMT2ALMNAKDM4E | |
| SCHEMBL23495185 | 0.81 | MEN1 (0.61) | POLBMEN1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4473968-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4149620-B1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | POLB 1270/4885MEN1 4101/4885KMT2A 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.